Rituximab Biosimilars in India — What the Price Gap Actually Means

They share the same international nonproprietary name, rituximab, and they target the same CD20 molecule. However, no two biological medicines are chemically identical at the molecular level — this is also true of two batches of the same originator product, because they are produced in living cells that introduce small natural variations. CDSCO approval means the regulator has assessed the biosimilar as comparable to the originator in quality, safety and efficacy. 'Comparable' is the precise regulatory term and is more accurate than 'identical.'

Reditux, manufactured by Dr. Reddy's Laboratories, was approved by CDSCO in 2007 — the world's first rituximab biosimilar. Several others have received CDSCO approval in subsequent years, including Maball. The approved list changes as new products are reviewed, so the most reliable current source is the CDSCO product register or the pharmacist at your treating hospital. Your oncology team will use the product their centre carries, and all products available in the hospital pharmacy should have valid CDSCO approval.

The price difference is substantial and widely reported, but no single figure is reliable here. Prices vary by hospital, city, volume purchased, and whether treatment is covered by a government scheme or insurer. Multiple health-economics analyses have described Indian rituximab biosimilars as available at a fraction of the originator cost. The actual figure at your centre is the only one that matters for your planning, and your oncology team or hospital pharmacist can give you that before treatment starts. Cost alone is never the basis for choosing which product is used.

This is a clinical decision for your oncologist. ESMO guidance on biological medicines notes that switching between an originator and a biosimilar should involve a clinical discussion about your individual situation — including which cycle you are on and how your disease is responding. In many cases a switch is practicable and many patients transition without difficulty. In some situations your oncologist may have a reason to continue with the product already started. Raise the question with your team if cost or availability is a concern; do not make the switch on your own.

Hospitals in India procure rituximab products through their own pharmacy and supply chains. The brand available at a given centre reflects procurement contracts and formulary decisions made by that institution — not a clinical preference for one approved product over another. All CDSCO-approved products have been assessed against the same regulatory standard. If you want to understand your centre's choice, the hospital pharmacist is the right person to ask.

CDSCO approval means the product has been assessed as comparable to the originator — that is what the regulatory process is designed to establish. Whether rituximab is appropriate for your cancer, and how well treatment is likely to perform, depends on whether your tumour expresses CD20, your cancer type and stage, and your overall fitness. Those factors are far more relevant than which approved brand is used. Your oncologist can explain what your own test results mean for your individual treatment plan.